Clinical Trial Update: A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months

View source ↗

Summary

Pfizer's Prevnar 20 pneumococcal vaccine is being studied for safety in infants aged 2 to 6 months, and the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 20 (20-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Status: ACTIVE_NOT_RECRUITING